Forest Support Services
SPECULATIVE BUYTraffic management specialist Forest Support Services grew earnings in the traditionally weaker first half and offers decent organic growth potential in resilient road repair, maintenance and improvement markets.
Formerly Transport Systems, Newport-based Forest operates in Wales and the South and West of England, where its activities include the design of traffic management systems and the supply of temporary fencing and road signs, as well as work on road framework projects. In an encouraging first half, pre-tax profits accelerated from £42,000 to £186,000 on turnover increased 25% to £4.34m (2008: £3.46m), with cash at the half-year improved to £421,000 (2008: £377,000).
Christopher Powell, chairman, flagged up strong trading at the Newport depot, driven by burgeoning sales from existing framework contracts and a pleasing performance over the summer. Meanwhile, trading at depots in Bristol and Winchester was in line with expectations.
Though the second half is historically stronger, the beginning of this year’s latter half has been 'less strong’ than in previous years, with Forest encountering project delays, and public spending cuts could constrain earnings. Having said that, infrastructure maintenance investment is largely non-discretionary and Forest’s recent financials have impressed, with the company moving from losses of £366,000 to profits of £215,000 in the year to last March, despite a drop in revenues to £6.75m (£6.8m).
With a tiny market capitalisation, Forest represents a high-risk punt, although given its recent growth journey and the fact the shares sell for less than nine times historic earnings, it is worthy of a speculation.
- Reduce text size Decrease text size
- Increase text size Increase text size
- Print article Print
- Share this article Share
- Email article to a friend Email
Market cap: £1.31m
Share price: 7p
Subscribe today
More breaking news stories.
More extended feature articles.
And a depth of analysis you
can't find anywhere else.
Advertisement
VCT Report 2010
VCT Report 2010 uncovers the money available
for investment in every single VCT, helping you get one step ahead in the race to attract funding for your unquoted, AIM-listed or PLUS-quoted
company.
Order VCT Report 2010 today using this online form
Cash Shells Directory 2010
A comprehensive overview of cash shells on AIM and PLUS, companies that have become a significant feature on the market landscape. For more information and to order, click here or contact our marketing team on 020 7250 7056.
Coverage of AIM, techMARK and PLUS Markets
Informative features and research on fast-growing companies, small-cap and growth stocks, penny shares, stock market tips and share recommendations, directors' dealings, company news and analysis, new issues and upcoming IPOs.
Take control of your investments
A full year's subscription to What Investment magazine for £19.95, a whopping 58% off. Get the latest news, features and expert advice on ISAs, Investment Trusts and Funds, SIPPS, Investing for Children and much much
more. Find out more here.
The Financial Times Guide to Personal Tax
is the definitive and most up-to-date guide to completing your self-assessment tax return, making sure that you get it right and on time, and showing how you can save tax. For more information and to order, click here or contact our marketing team on 020 7250 7056.
The AIM Guide Spring 2010
The new, fully updated AIM Guide is now available to buy for only £49.95 (saving you £30).
A 'must-have' for any serious investor or professional interested in the market for young, fast-growing companies. Order your copy today Hurry, as offer ends soon!
Share recommendations and small-cap stock picks
Small-cap and growth company share recommendations on AIM- and PLUS-listed companies. Latest analysts' stock tips and advice on which are the best shares to buy on London's junior stock markets.
Popular Recommendations
Advertisement
Latest Recommendations
Delcam 01/09/2010
Delcam, the international seller of CAD/CAM software to the engineering, aerospace and healthcare sectors among others, is a cash-generative small-cap seeing recovery in its markets.
Antisoma 01/09/2010
Bombed-out biotech play Antisoma is hoping two of its drugs will lead to good fortune after experiencing disaster with lung cancer treatment ASA404.
GW Pharmaceuticals 31/08/2010
GW Pharmaceuticals has won approval from Health Canada for its cannabis-based Sativex product to treat spasticity caused by Multiple Sclerosis.
Sectors
